GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » Float Percentage Of Total Shares Outstanding

Oxurion NV (Oxurion NV) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Oxurion NV Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oxurion NV's float shares is 0.00 Mil. Oxurion NV's total shares outstanding is 2,551.31 Mil. Oxurion NV's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oxurion NV's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oxurion NV's Institutional Ownership is 0.00%.


Oxurion NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Oxurion NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/2,551.31
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxurion NV (Oxurion NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.